Managing Director and Chief Executive Officer of BioAdvance
Barbara Schilberg, JD has more than 30 years of experience working with academic technologies and start-up companies in the life sciences sector. Under her leadership as CEO, BioAdvance has committed $22.6 million to 32 seed-stage companies and 24 pre-seed projects focusing in areas including Alzheimer’s disease, cancer, diabetes, obesity and infectious diseases. The BioAdvance portfolio companies have leveraged $1.5 billion in subsequent capital from venture capital, grants, collaborations, M&A activity and product revenues. Seven portfolio companies have been acquired, one company has completed an initial public offering, and one exited through a refinancing. Ms. Schilberg is a board member or serves as an observer on the boards of several BioAdvance portfolio companies including Immunome, Jenrin Discovery, Marillion Pharmaceuticals, Melior Pharmaceuticals, Novira Pharmaceuticals, and QR Pharma. As a senior executive with four emerging life sciences companies, Ms. Schilberg’s prior experience provides significant insight into the key elements needed to build successful companies including public and private financings, intellectual property protection, corporate partnering arrangements and the management of research programs. She joined Cephalon in 1994 as Senior Vice President and General Counsel and as a member of the executive committee. As part of her responsibilities, she led a multi-disciplinary team charged with completing Phase III clinical trials and preparing a new drug application for PROVIGIL® (modafinil), which was approved by the FDA in December 1999. She joined Incara Pharmaceuticals in 1998 as Executive Vice President and General Counsel, where she managed a research operation in Princeton, NJ engaged in discovering new antibacterial therapeutics. She continued in that capacity after the operation’s acquisition by Advanced Medicine (now Theravance) in 2000. Ms. Schilberg also served as Vice President and General Counsel at Locus Discovery, Inc., an emerging pharmaceutical company in Blue Bell, PA engaged in computational drug design. Before joining industry, Ms. Schilberg specialized in representing biopharmaceutical companies and research institutions in the commercialization of technology, as a partner in the Philadelphia office of Morgan, Lewis & Bockius. Ms. Schilberg received a JD from the University of Virginia and clerked with the Honorable Edward R. Becker, now Senior Judge of the U.S. Court of Appeals for the Third Circuit.